Neuroprotective Effects of OMO within the Hippocampus and Cortex in a D-Galactose and Aβ_25–35-Induced Rat Model of Alzheimer’s Disease

Figure 2

Effect of OMO on latency in D-galactose and Aβ_25–35-treated AD rats. Control, control group; Sham, sham-operated group; Model, model group (D-galactose and Aβ_25–35 10 μg + saline); Positive, positive group (D-galactose and Aβ_25–35 10 μg + Aricept 0.4 mg/kg); OMO-120 mg, low-dose OMO group (D-galactose and Aβ_25–35 10 μg + OMO 120 mg/kg); OMO-240 mg, middle-dose OMO group (D-galactose and Aβ_25–35 10 μg + OMO 240 mg/kg); and OMO-480 mg, high-dose OMO group (D-galactose and Aβ_25–35 10 μg + OMO 480 mg/kg). These values given are the mean ± SD. n = 10.